Accessibility Statement Skip Navigation
  • PRNewswire.com
  • Resources
  • +91 22-69790010
  • Client Login
  • Send a Release
PR Newswire: news distribution, targeting and monitoring
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please use Advanced Search to search all press releases.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • Telephone

    • +91 22-69790010 from 9 AM - 5:30 PM IST

    • Contact
    • Contact

      +91 22-69790010
      from 9 AM - 5:30 PM IST

  • Request More Information
  • Journalists
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Request More Information
  • Journalists
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Request More Information
  • Journalists
  • General Inquiries
  • Worldwide Offices
  • Request More Information
  • Journalists

Global Oncolytic Virus Therapy Clinical Trials Research Immunotherapy Market Insight 2026
  • USA - English

Currently There Are More Than 125 Oncolytics Virus Therapy Based Immunotherapies In Clinical Trials Says Kuick Research

Kuick_Research_Logo

News provided by

Kuick Research

19 Apr, 2021, 08:41 IST

Share this article

Share toX

Share this article

Share toX

DELHI, India, April 18, 2021 /PRNewswire/ --

"Global Oncolytic Virus Immunotherapy Market, Dosage, Price & Clinical Trials Outlook 2026" Report Highlights:

  • Global Oncolytic Virus Immunotherapy Market: US$ 700 Million Opportunity
  • Global Oncolytic Virus Immunotherapy Clinical Trials: >125 Therapies In Trials
  • USA Dominates Oncolytic Virus Immunotherapy Clinical Trials: >50 Therapies In Trials
  • Comprehensive Insight on Clinical & Non Clinical Issues Related to Global Oncolytic Virus Immunotherapy Market Development
  • Approved Oncolytic Virus Immunotherapy: 2
  • Global Research Progress & Medical Advancement Insight
  • Imlygic (Talimogene laherparepvec) & Oncorine: Dosage, Price & Patent insight

Download Report:  https://www.kuickresearch.com/report-oncolytic-virus-immunotherapy-market-size-sales-clinical-trials-cancer-oncology-melanoma-report-talimogene-laherparepvec-imlygic--oncorine

The ability of the researchers to use viral particle for enhancing the immune response against the cancer cells is estimated to get recognized as a unique platform for treating cancer patients. The interface developed by the market in short period of time at clinical and pre-clinical level is estimated to completely transform the entire cancer therapeutics landscape towards a pattern that is not observed or reported through the means of any other cancer therapy available such as chemotherapy or hormonal therapy. Global oncolytic virus immunotherapy market is a novel cancer treatment platform which is engineered to deliver maximum results for the cancer patients in a controlled way. Although efficiency with viral particle in the treatment of cancer is very low, however continuous clinical research activities followed for the market has led to the development of a more precise mechanism of targeting cancer cells with the help of viral particles.

The research report developed for global oncolytic virus immunotherapy however discusses all the potential applications of the therapy with respect to the treatment of different types of cancers and its healthcare benefits when compared with other potent cancer therapies. In addition to it, the research report also discusses the success storied for the market at pre-clinical and clinical level. It is estimated that the market in long-term is believed to precisely correct all the limitations that were observed for long period of time in the current market. As per the research conducted, the therapy is a novel therapy which has been developed by the researchers all across the globe keeping in view the increasing burden of the cancer cases and the high failure rate observed for the commercially available therapies.

The clinical platform developed by the market involves all the applications that are however responsible for over-shadowing the challenges that were delivering low survival rate in the patients. The current healthcare benefits received through the platform is believed to seek the interest of hundreds of drug makers and research firms in order to drive the future of the market which indeed is of great importance as per the view of the current details of the cancer therapeutics market.

The vast and robust clinical pipeline available for the market is estimated to face severe appreciation and acceptance by the researchers and the patients. In a more efficient way, the therapy at clinical levels has led to the significant advancement of the global cancer therapeutics market. In addition to this, the presences of potential market parameters acting as driver are estimated to potentially run the market towards success. Some of the potential drivers associated with the market are: unlimited advantages of the market, limited off-targeting by the potential drugs, high survival rate and many more. All these are witnessed to be inclining the market towards high growth rate and market size in the future years.

The current clinical market associated with global oncolytic virus immunotherapy is estimated to be the result of extensive clinical research activities that have been conducted by the researchers all across the globe. In a short period of time, the platform has been able to significantly impact the overall current cancer therapeutics market. It can be estimated that the complete emergence of novel therapeutic approach by the researchers for the use by the patients will completely revolutionize the cancer therapeutics market towards more successful and innovative market. As per the research conducted, it is estimated that the strong association of the market with potential investigational drugs will conquer hundreds of more healthcare applications and multiple million-dollar partnerships and collaborations among elite research centers and bio-pharmaceutical companies for overall regulation of the market in the upcoming years.

Contact:
Neeraj Chawla
Research Head
+91-981410366
[email protected]
https://www.kuickresearch.com

Logo: https://mma.prnewswire.com/media/1245952/Kuick_Research_Logo.jpg

Modal title

Contact PR Newswire

  • +91 22-69790010

Global Sites

  • APAC
  • APAC - Traditional Chinese
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany

 

  • India
  • Indonesia
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland

 

  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921
Global Sites
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • United States
+91 (0) 22 6169 6000
from 9 AM - 5:30 PM IST
  • Terms of Use
  • Privacy Policy
  • GDPR
  • Information Security Policy
  • Site Map
  • Cookie Settings
Copyright © 2025 Cision US Inc.